title: Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis.
abstract: Severe sepsis leads to massive activation of coagulation and complement cascades that could contribute to multiple organ failure and death. To investigate the role of the complement and its crosstalk with the hemostatic system in the pathophysiology and therapeutics of sepsis, we have used a potent inhibitor (compstatin) administered early or late after Escherichia coli challenge in a baboon model of sepsis-induced multiple organ failure. Compstatin infusion inhibited sepsis-induced blood and tissue biomarkers of complement activation, reduced leucopenia and thrombocytopenia, and lowered the accumulation of macrophages and platelets in organs. Compstatin decreased the coagulopathic response by down-regulating tissue factor and PAI-1, diminished global blood coagulation markers (fibrinogen, fibrin-degradation products, APTT), and preserved the endothelial anticoagulant properties. Compstatin treatment also improved cardiac function and the biochemical markers of kidney and liver damage. Histologic analysis of vital organs collected from animals euthanized after 24 hours showed decreased microvascular thrombosis, improved vascular barrier function, and less leukocyte infiltration and cell death, all consistent with attenuated organ injury. We conclude that complement-coagulation interplay contributes to the progression of severe sepsis and blocking the harmful effects of complement activation products, especially during the organ failure stage of severe sepsis is a potentially important therapeutic strategy.
authors.affiliation: Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Silasi-Mansat
authors.forename: Hua
authors.initials: H
authors.lastname: Zhu
authors.forename: Narcis I
authors.initials: NI
authors.lastname: Popescu
authors.forename: Glenn
authors.initials: G
authors.lastname: Peer
authors.forename: Georgia
authors.initials: G
authors.lastname: Sfyroera
authors.forename: Paola
authors.initials: P
authors.lastname: Magotti
authors.forename: Lacramioara
authors.initials: L
authors.lastname: Ivanciu
authors.forename: Cristina
authors.initials: C
authors.lastname: Lupu
authors.forename: Tom E
authors.initials: TE
authors.lastname: Mollnes
authors.forename: Fletcher B
authors.initials: FB
authors.lastname: Taylor
authors.forename: Gary
authors.initials: G
authors.lastname: Kinasewitz
authors.forename: John D
authors.initials: JD
authors.lastname: Lambris
authors.forename: Florea
authors.initials: F
authors.lastname: Lupu
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects* / Q000276:immunology; D001794:Blood Pressure / Q000187:drug effects; D003167:Complement Activation / Q000187:drug effects; D003169:Complement Inactivator Proteins / Q000378:metabolism / Q000494:pharmacology*; D016207:Cytokines / Q000097:blood; D004195:Disease Models, Animal; D004927:Escherichia coli Infections / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D009102:Multiple Organ Failure / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D010215:Papio; D010456:Peptides, Cyclic / Q000494:pharmacology*; D018805:Sepsis / Q000097:blood / Q000188:drug therapy / Q000276:immunology
chemical_list: D015415:Biomarkers; D003169:Complement Inactivator Proteins; D016207:Cytokines; D010456:Peptides, Cyclic; C111828:compstatin
references.citation: Immunol Today. 1991 Sep;12(9):338-42
references.pmid: 1755945
references.citation: J Med Chem. 2006 Jul 27;49(15):4616-22
references.pmid: 16854067
references.citation: J Cell Mol Med. 2009 Oct;13(10):4154-60
references.pmid: 19725914
references.citation: Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15861-6
references.pmid: 19717455
references.citation: Clin Immunol. 2000 Sep;96(3):212-21
references.pmid: 10964539
references.citation: Adv Exp Med Biol. 2008;632:253-63
references.pmid: 19025127
references.citation: J Immunol. 2005 Feb 15;174(4):2143-51
references.pmid: 15699145
references.citation: Thromb Res. 2004;114(5-6):321-7
references.pmid: 15507261
references.citation: Mol Immunol. 2003 Jan;39(10):557-66
references.pmid: 12431389
references.citation: Mol Immunol. 2008 Aug;45(14):3804-13
references.pmid: 18606453
references.citation: Am J Pathol. 2003 Feb;162(2):449-55
references.pmid: 12547703
references.citation: Am J Pathol. 2005 Oct;167(4):1161-72
references.pmid: 16192650
references.citation: J Exp Med. 1983 Aug 1;158(2):603-15
references.pmid: 6604123
references.citation: Blood. 2002 Jul 15;100(2):517-23
references.pmid: 12091343
references.citation: J Immunol. 1996 Jul 15;157(2):884-91
references.pmid: 8752942
references.citation: Blood. 2007 Nov 1;110(9):3168-75
references.pmid: 17644733
references.citation: Crit Care Med. 2001 Jul;29(7):1303-10
references.pmid: 11445675
references.citation: Trends Immunol. 2007 Apr;28(4):184-92
references.pmid: 17336159
references.citation: J Cell Mol Med. 2008 Dec;12(6A):2245-54
references.pmid: 18798865
references.citation: J Exp Med. 2005 Mar 21;201(6):871-9
references.pmid: 15781579
references.citation: Prog Clin Biol Res. 1994;388:175-94
references.pmid: 7831358
references.citation: Infect Immun. 1993 Oct;61(10):4293-301
references.pmid: 8406818
references.citation: Circ Shock. 1993 Feb;39(2):83-8
references.pmid: 8490996
references.citation: BMC Genomics. 2007 Feb 26;8:58
references.pmid: 17324256
references.citation: Crit Care Med. 2005 Oct;33(10):2214-21
references.pmid: 16215373
references.citation: Adv Exp Med Biol. 2006;586:203-16
references.pmid: 16893074
references.citation: Blood. 2007 Apr 15;109(8):3161-72
references.pmid: 17110453
references.citation: Am J Pathol. 2007 Sep;171(3):715-27
references.pmid: 17640961
references.citation: Blood. 2000 Mar 1;95(5):1680-6
references.pmid: 10688824
references.citation: FASEB J. 2010 Mar;24(3):712-22
references.pmid: 19841036
references.citation: Nat Rev Immunol. 2004 Feb;4(2):133-42
references.pmid: 15040586
references.citation: J Biol Chem. 2007 Oct 5;282(40):29241-7
references.pmid: 17684013
references.citation: Clin Exp Immunol. 1993 Feb;91(2):295-300
references.pmid: 7679061
references.citation: J Clin Immunol. 1996 Jul;16(4):222-9
references.pmid: 8840224
references.citation: N Engl J Med. 2009 Jul 23;361(4):345-57
references.pmid: 19625716
references.citation: J Immunol. 2010 Mar 1;184(5):2686-92
references.pmid: 20139276
references.citation: Crit Care Med. 2001 Jul;29(7 Suppl):S78-89
references.pmid: 11445739
references.citation: Am J Pathol. 2007 Sep;171(3):1066-77
references.pmid: 17640967
references.citation: Nat Med. 2006 Jun;12(6):682-7
references.pmid: 16715088
references.citation: Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22405-10
references.pmid: 20018737